Being fresh from DMEA this month, I still see a concerning problem for EU digital health companies: hospitals and clinics are (still) reluctant to adopt cloud solutions.

It seems that it is impossible to benefit from AI advantages while keeping patient data intact and safe. To overcome this, several AI companies have found the answer to many problems in synthetic data: data sharing, algorithm training, and collaboration with third parties.

When it comes to GDPR, the biggest misconception is that compliance is a one-off project and that once you have checked all the boxes, you don’t have to worry about it anymore.

Not taking into account the importance of protecting your users’ privacy and their personal data may damage your brand reputation and get you out of business. We saw companies lose deals in B2B and B2C startups lose partnerships and reimbursement agreements.

The AI Act is not in force yet. On 14 June 2023, the Members of the EU Parliament adopted Parliament's negotiating position on the AI Act.

With the Access Prescription Digital Therapeutics Act, we may witness a change that promises to transform healthcare delivery with benefits for both digital health companies and millions of American citizens.

France has introduced a fast-track market access pathway for DTx and digital health products, adding to similar schemes in neighboring EU countries Germany (DVG for DiGA) and Belgium.

In this blog article, we will go through this topic from the POV of a digital health startup and try to give you a better understanding of when you should ask for consent and why.

Italy’s data protection authority has ordered OpenAI to stop processing people’s data locally with immediate effect. The Italy DPA claims that ChatGPT is breaching the GDPR due to unlawful data processing.